Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Steve Harmon who wrote (1084)	3/30/1998 2:29:00 PM
From: BrainTrust	Read Replies (1) \| Respond to of 2742

How do we get a shareholder vote on cashing out on the ballot?

To: Steve Harmon who wrote (1084)	3/31/1998 8:48:00 AM
From: Dr. John M. de Castro	Read Replies (2) \| Respond to of 2742

CIST - Bluestone renewal. This is not very informative beyond the headline. John de C Cistron Biotechnology Extends Agreement With BlueStone Capital Partners PINE BROOK, N.J., March 31 /PRNewswire/ -- Cistron Biotechnology, Inc. (OTC: CIST - news) has renewed its agreement with BlueStone Capital Partners, L.P., New York-based investment banking firm, for another six months it was announced today. ''Since September, 1997 Cistron and BlueStone have worked closely together in several areas including corporate strategic partnering with the goal of enhancing shareholder value. Today's contract extension enables us to continue our efforts,'' stated Bruce C. Galton, Cistron's acting chief executive officer. Robert W. Naismith, Ph.D., BlueStone's managing director of healthcare, was elected to Cistron's board of directors in January, 1998.